SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-04
👔
Inhibitor Therapeutics, Inc.
@INTI_InsiderForm 4 Filing: Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012 Acquires (Grant) shares of $INTI
STOCK AWARD / GRANT
⚡ MATERIALITY: 1/10
corporate issuer
Inhibitor Therapeutics, Inc.
Ticker: $INTI
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-05-04
Shares: 50,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012, holds the title of 10% Owner at Inhibitor Therapeutics, Inc..
On 2026-05-04, the insider transacted 50,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Ronald E. Osman Irrevocable Trust III under Agreement dated May 13, 2012 (10% Owner) was granted $0 of $INTI
Post-Transaction Position: 23,614,985 shares
SEC Accession No: 0001493152-26-035962 (CIK: 1972372)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.